In this study, we investigated the potential of a combinatorial treatment with small molecules targeting key components of the MAPK pathway, namely BRAF and MEK, in KRAS-mut NSCLC and PDAC. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.